Study of some immunopharmacological properties of XXXX in experimental schistosomiasis mansoni.

@entity738 @entity19 @entity383 @entity56 @entity380 @entity99 @entity2039
The immunopharmacological properties of @entity2039 were studied in @entity19 infected with @entity380 . @entity99 measurement was the main parameter of assessment. Delayed foot pad swelling as an in vivo correlate for the delayed granulomatous @entity56 was also determined. Fluorescent direct antigen-antibody reaction in the @entity738 together with the immediate foot pad swelling were used to test for the humoral immune response. @entity2039 administered at seven weeks after infection in two dose regimens (3 X 250 mg kg-1 for three consecutive days and 3 X 83 mg kg-1 given four hourly within the same day was more or less equally effective in reducing the size of hepatic @entity738 by 37-41% two weeks after treatment and by 81-85% one month after treatment. Delayed foot pad swelling using soluble egg antigen (SEA) was significantly suppressed one month after treatment by 53%. At nine weeks after infection the fluorescent antigen-antibody reaction in the @entity738 was positive in the untreated controls, but at the same time (i.e. two weeks after treatment) it was negative in the @entity2039 -treated @entity19 . One month after treatment positivity was less compared to infected control @entity19 . Reduction in worm burden, hepatic shift of the worms and the reduced number of ova per gram of tissue denoted the efficacy of the drug in its two dose regimens against the Egyptian strain of @entity383 .
